The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
MajesTEC-5 Latest data: Teclistamab-DR ± bortezomib for TE-NDMM
|
The first-in-class BCMA–directed bispecific antibody teclistamab is approved for the treatment of patients with triple-class exposed RRMM and is now under investigation in earlier lines of therapy. Daratumumab-based triplet and quadruplet therapies (DRd and DVRd) have demonstrated improved survival in transplant-eligible (TE) NDMM. MajesTEC-5 (NCT05695508) is a phase II study evaluating teclistamab in combination with DR, with or without bortezomib, for TE-NDMM. During ASH 2024, Marc Raab presented initial outcome data from three induction cohorts in the MajesTEC-5 trial (Arm A: Tec-DR QW (n = 10); Arm A1: Tec-DR Q4W (n = 20); Arm B: Tec-DVR Q4W (n = 19).1 |
| Key learnings |
| The ORRs were 100%, 90%, and 89.5% in Arms A, A1, and B, respectively. An sCR rate of 100% was observed in Arm A, with deepening responses in maturing cohorts. 100% of evaluable patients achieved MRD negativity by Cycle 3. |
| Neutropenia was the most common hematologic TEAE. Notably, the addition of bortezomib in Arm B did not lead to a higher incidence of thrombocytopenia. Among the most common nonhematologic TEAEs, rates of Grade 3/4 events were low. |
| 34.7% of patients experienced Grade 3/4 infections, primarily URTI and COVID-19, with no discontinuations or Grade 5 infections. Hypogammaglobulinemia occurred in 91.8% of patients, with 89.8% receiving IVIG as infection prophylaxis. |
| Overall, induction with Tec-DR and Tec-DVR for TE-NDMM showed high efficacy with 100% MRD-negativity after Cycle 3 maintained to Cycle 6, no TEAE-related discontinuations, and feasible stem cell mobilization. |
Abbreviations: BCMA, B-cell maturation agent; D, daratumumab; DRd, daratumumab, lenalidomide, and dexamethasone; DVRd, daratumumab, bortezomib, lenalidomide, and dexamethasone; IVIG, intravenous immunoglobulin; MRD, measurable residual disease; n, number; NDMM, newly diagnosed multiple myeloma; ORR, overall response rate; QW, once per week; Q4W, once every 4 weeks; R, lenalidomide; RRMM, relapsed/refractory multiple myeloma; sCR, stringent complete response; TE, transplant-eligible; TEAE, treatment-emergent adverse event; Tec, teclistamab; URTI, upper respiratory tract infection; V, bortezomib.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
